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Background: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and
their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at
relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-
conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease. The aim of our study
was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI).
Methods: Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI
attributed to a wide range of drugs. Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing
HPLC followed by DNA sequencing. The functional impact of keratin variants was assessed using cell transfection and
immune staining.
Results: Heterozygous and compound amino acid-altering K8/K18 variants were identified in 86 DILI patients and
non-coding variants in 15 subjects. Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8
Ile346Val, K18 Asp89His) and two non-coding variants were observed. Several variants segregated with specific
ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population
controls. Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18
Asp89His (isoniazid-related) were found in patients with fatal DILI. These novel variants also led to keratin network
disruption in transfected cells.
Conclusions: Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with
fatal DILI. Other non-cytoskeleton-disrupting keratin variants did not preferentially associate with DILI.
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Keratins (Ks) represent a subgroup of intermediate fila-
ments (IFs) found mainly in epithelial tissues [1–3]. As
for all IFs, they display a tripartite structure containing a
conserved α-helical central rod domain that is flanked
by a less conserved N-terminal head and C-terminal tail
domains [4, 5]. Keratins are further subdivided into the
relatively acidic type I (including K9–K28 and K31–K40)
and relatively basic type II IFs (including K1–K8 and
K71–K86) that associate as obligate non-covalent het-
eropolymers [6, 7]. Consequently, every cell type* Correspondence: pstrnad@ukaachen.de
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article, unless otherwise stated.contains a characteristic type I–II expression pattern
[1, 7]. For example, K1/K10 and K5/K14 are the
major keratins of suprabasal and basal keratinocytes,
respectively, while K8/K18/K19/K20 are the keratins
found in simple type glandular epithelia [2, 8]. Adult
hepatocytes are unique in that they only contain K8/K18,
while most other cell types display a more complex kera-
tin expression pattern [8, 9]. It is this heteropolymeric
keratin–keratin association that accounts for the amino
acid position-selective dominant negative effect of het-
erozygous keratin mutations in human disease.
Keratins are established cytoprotective proteins [10, 11]
and keratin mutations lead or predispose to the develop-
ment of >60 distinct human diseases [2, 12, 13] that are
faithfully reproduced in transgenic animals models [8, 14].icle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
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phenotype under basal conditions, but predispose to sig-
nificant injury from a variety of stresses including apop-
totic, metabolic, oxidative and drug-induced [11, 15–17].
Human association studies have identified keratin variants
to be overrepresented in patients with end-stage liver dis-
ease, acute liver failure (ALF), chronic hepatitis C virus
infection or primary biliary cirrhosis, and to predispose to
adverse clinical outcomes [8, 18, 19].
Human studies also revealed marked differences in
ethnic distribution of keratin variants. For example, K8
G62C and K8 R341H were the most abundant amino
acid substitutions in Caucasians, while African-
American (AA) subjects displayed high frequencies of
K8 A333A and G434S variants [19]. Importantly, K8/
K18 variants were found in the less conserved protein
regions and did not affect keratin organization under
basal conditions, while disease-causing mutations in epi-
dermal keratins cluster in the most conserved subdo-
mains at the amino and carboxyl regions of the rod
domain, and often result in keratin network breakdown
[2, 8, 14, 20]. For example, K14 R125C leads to the most
severe Dowling Meara form of epidermolysis bullosa
simplex (EBS) [14]. The homologous K18 alteration
(K18 R90C) that was engineered in transgenic animals
results in a disruption of filamentous hepatocellular
keratin network, mild chronic hepatitis and distinct sus-
ceptibility to various hepatotoxic stresses [8, 15].
Given the murine data suggesting keratin mutation-
associated susceptibility to chemical hepatotoxicity and
human studies linking K8/K18 variants to acetamino-
phen hepatotoxicity [19], we hypothesized that K8/K18
variants may contribute to the susceptibility to human
idiosyncratic drug-induced liver injury (DILI) that is a
prominent cause of ALF [21, 22]. DILI is also a major
adverse event leading to termination of clinical drug devel-
opment programs [23]. Several previous studies suggested
that DILI has a genetic component with variants in human
leukocyte antigens and drug metabolizing enzymes increas-
ing risk for development of DILI [22, 24]. We tested our
hypothesis by analyzing 800 consecutive DILI subjects en-
rolled in the ongoing DILI Network (DILIN) study and
identified several novel K8/K18 variants.
Methods
Study participants
Between August 2004 and April 2009, 808 subjects were
recruited from eight US clinical sites participating in the
DILIN. Details of the inclusion/exclusion criteria were
previously described [25]. DILI causality assessment and
severity was based on consensus of a panel of experi-
enced hepatologists [25]. The cases were subdivided into
hepatocellular, cholestatic or mixed injury pattern based
on the R-value [25, 26]. All participants provided writteninformed consent, which included collection of DNA for
genetic association studies, and the study was approved
by the local institutional review boards of the participat-
ing centers (see list in the Acknowledgements section).
For control data of keratin variants in Caucasian and
African-American subjects, we used the Exome Sequencing
Project database available through the Exome Variant
Server [27] whereas the 1000 Genomes project data [28]
were employed for Hispanic and Asian controls.
Genetic analysis
Genomic DNA was obtained from EDTA-anticoagulated
peripheral blood with a DNeasy Tissue Kit (Qiagen,
Valencia, CA, USA). The mutational K8/K18 hotspots
(K8 exons 1, 6, 8 (corresponding to amino acids 1–108,
328–400, 421–483); K18 exon 1 (corresponding to
amino acids 1–139) and their adjacent exon-intron
boundaries) were PCR-amplified using AmpliTaq Gold®
DNA Polymerase (Applied Biosystems, Foster City, CA,
USA) and previously described primers [29]. The selection
of these hotspots is based on more than 2,000 human sub-
jects in whom the entire K8/K18 exonic regions were ana-
lyzed [17–19, 29, 30]. All PCR products were pre-screened
with the WAVE® denaturing HPLC system (Transgenomic,
Omaha, NE, USA). Specimens with an abnormal elution
peak were confirmed in an independent PCR analysis,
purified and subjected to bidirectional DNA sequencing.
Annotation of coding K8/K18 variants was made with the
mRNA sequences NM_002273.3/NM_000224.2, while the
sequences M34482.1/AF179904.1 were used for non-
coding changes. The conservation of the observed K8/K18
variants was analyzed using the following sequences:
K8: NP_002264.1 (human), NP_112447.2 (mouse), NP_
001028782.1 (cow), NP_001080525.1 (frog), NP_956374.1
(zebrafish); K1 (NP_006112.3), K2 (NP_000414.2), K3
(NP_476429.2), K4 (NP_002263.2), K5 (NP_000415.2), K6a
(NP_005545.1), K7 (NP_005547.3); K18: NP_000215.1
(human), NP_034794.2 (mouse), NP_001179024.1 (cow),
NP_001089734.1 (frog), NP_848524.1 (zebrafish); K9
(NP_000217.2), K10 (NP_000412.3), K12 (NP_000214.1),
K13 (NP_705694.2), K14 (NP_000517.2), K15 (NP_
002266.2), K16 (NP_005548.2), K17 (NP_000413.1), K19
(NP_002267.2), K20 (NP_061883.1). Given that eight sam-
ples were not reliably amplified, 800 samples were included
in the final analysis.
Statistical analysis
The Fisher’s exact test was used to determine non-
random associations between two variables, and P values
less than 0.05 were considered statistically significant.
Cell culture experiments
To study the biological significance of novel K8/K18
variants, human K8 and K18 cDNA inserted in the
Table 1 Characteristics of the DILI cohort
Gender Male Female Total
335 (41.9) 465 (58.1) 800 (100)
Ethnicity/race AA Asian Caucasian Hispanic Other
87 (10.9) 25 (3.1) 577 (72.1) 88 (11.0) 23 (2.9)
Causalitya Definitive Very likely Probable Possible Unlikely
190 (23.8) 312 (39.0) 148 (18.5) 110 (13.8) 39 (4.9)
Injury type Hepatocellular Cholestatic Mixed
438 (54.8) 198 (24.7) 164 (20.5)
Severity Fatal (5) Severe (4) Mod hosp (3) Mod (2) Mild (1)
71 (8.9) 144 (18.0) 221 (27.6) 176 (22.0) 188 (23.5)
Absolute numbers are shown followed by percentages in brackets. aCausality score was unknown in one patient. AA, African-American; DILI, drug-induced liver injury;
Mod, moderate non-hospitalized; Mod hosp, moderate hospitalized
Table 2 Distribution of keratin variants in DILI patients stratified by subject race/ethnicity
Race/ethnicity
AA Asian Caucasian Hispanic Other Total
# (%) # (%) # (%) # (%) # (%) # (%)
Nucleotide Variant dbSNP ID 87 (10.9) 25 (3.1) 577 (72.1) 88 (11.0) 23 (2.9) 800 (100)
160 T>C K8 Y54H rs57749775 0 0 0 1 (1.1) 0 1 (0.1)
184G>T K8 G62C rs11554495 0 0 10 (1.7)c 0 1 (4.3) 11 (1.4)
187A>G K8 I63V rs59536457 0 0 8 (1.4) 0 1 (4.3) 9 (1.1)
IVS1+30G>Ae K8 Intr - 0 0 1 (0.2) 0 0 1 (0.1)
999C>T K8 A333A rs7750 13 (14.9)a 0 0 2 (2.3) 0 15 (1.9)
1022G>A K8 R341H rs57422427 1 (1.1)b 1 (4.0) 27 (4.7)c 9 (10.2) 2 (8.7) 40 (5.0)
1036A>Ge K8 I346V - 0 0 1 (0.2)d 0 0 1 (0.1)
1052C>Te K8 A351V - 0 0 1 (0.2) 0 0 1 (0.1)
1073C>Te K8 A358V - 0 0 1 (0.2) 0 0 1 (0.1)
1138G>A K8 V380I rs56997521 0 0 3 (0.5) 0 0 3 (0.4)
1178A>Ge K8 K393R - 0 0 1 (0.2) 0 0 1 (0.1)
IVS6+46A>T K8 Intr rs189690662 0 0 9 (1.6)d 0 1 (4.3) 10 (1.3)
1300G>A K8 G434S rs58573614 10 (11.5)a 0 0 0 0 10 (1.3)
1383G>Te K8 V461V - 0 1 (4.0) 0 0 0 1 (0.1)
1438G>A K8 V480I rs61730606 4 (4.6) 0 3 (0.5) 0 0 7 (0.9)
IVS8+8C>T K8 Intr rs201942002 0 0 0 1 (1.1) 0 1 (0.1)
IVS8+38G>A K8 Intr rs267607663 1 (1.1) 0 0 0 0 1 (0.1)
IVS8+27del9nte K8 Intr - 0 0 1 (0.2) 0 0 1 (0.1)
K18-11C>T K18 Intr - 1 (1.1)b 0 0 0 0 1 (0.1)
K18 Δ65-72 K18 Deletion rs267607417 0 0 0 1 (1.1) 0 1 (0.1)
265G>Ce K18 D89H - 0 1 (4.0) 0 0 0 1 (0.1)
# (%) patients with amino acid-altering variants 15 (17.2) 2 (8.0) 54 (9.4) 11 (12.5) 4 (17.4) 86 (10.8)
# (%) patients with intronic variants 2 (2.3) 0 11 (1.9) 1 (1.1) 1 (4.3) 15 (1.9)
The table displays the number of patients of different races/ethnicities harboring the listed keratin variants. aOne patient carries two K8/K18 variants (K8 A333A+G434S);
bone patient carries two K8/K18 variants (K8 R341H+K18-11C>T); cone patient carries two K8/K18 variants (K8 G62C+R341H); done patient carries two K8/K18
variants (K8 I346V+IVS6+46A>T); enovel variants, which were not previously described (includes five amino acid-altering variants). AA, African-American; DILI,
drug-induced liver injury
Usachov et al. BMC Medicine  (2015) 13:196 Page 3 of 12
Usachov et al. BMC Medicine  (2015) 13:196 Page 4 of 12pcDNA3.1 vector was modified with the QuikChange®
Site-Directed Mutagenesis Kit (Stratagene, Santa Clara,
CA, USA) and specific primers (hK8-I346V-F ctggga
gagctggccgttaaggatgccaacg, hK8-I346V-R cgttggcatccttaa
cggccagctctccacg; hK8-A351V-F cattaaggatgccaacgtcaag
ttgtccgagctgg, hK8-A351V-R ccagctcggacaacttgacgttggca
tccttaatg; hK8-A358V-F cgagctggaggtcgccctgcagc, hK8-
A358V-R gctgcagggcgacctccagctcg; hK8-K393R-F cgcca
cctacaggaggctgctggaggg, hK8-K393R-R ccctccagcagcctcc
tgtaggtggcg; hK18-D89H-F gcaaagcctgaaccaccgcctggcctc,Fig. 1 Distribution of the identified keratin 8/18 (K8/K18) variants within the
consisting of head, rod and tail domains with their corresponding amino ac
corresponding linker (L) sequences, L1, L1-2, L2, and the shaded regions at t
conserved helix initiation/termination motifs (HIM/HTM) that represent the m
genes is also depicted (E1–E8 for K8 and E1–E7 for K18). The exons that
coding variants are denoted by position and alteration of the affected a
intronic variants to the coding sequences is also shown. For annotation
and the position of a single variant located in the 5′UTR of K18 is deno
novel variants which were not previously described are highlighted in bold
the novel K8 K393R and K18 D89H represent the first described K8/K18 variahK18-D89H-R gaggccaggcggtggttcaggctttgc). The result-
ing constructs were verified by DNA sequencing. For
immunofluorescence staining, NIH 3T3 cells (CRL-1658;
American Type Culture Collection) were grown in
DMEM medium (Gibco, Life Technologies GmbH,
Darmstadt, Germany) supplemented with 10 % FCS, 1 %
penicillin-streptomycin and 1 % L-glutamine, and then
transfected with equal amounts of K8 or K18 variant
cDNA together with an equal amount of non-mutated
partner keratin (K18 or K8) cDNA using Lipofectamineprotein backbone. The schematics depict the tripartite keratin structure
id annotations. The rod subdomains IA, IB and II are connected by the
he beginning and end of the rod domain correspond to particularly
utational hotspots in epidermal keratins. The exonic structure of both
were analyzed in the present study are highlighted in bold. The
mino acid displayed by the single-letter code. The relation of the
of intronic variants, the intervening sequences are labeled as ‘IVS’
ted by its nucleotide (‘nt’) distance from the starting codon. The
and the absolute count of all variants is listed in parentheses. Note that
nts localized in the most conserved HTM/HIM regions
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Germany). Transfection of wild-type K8/K18 was
used as control. Transfected cells were fixed with
precooled −20 °C methanol (3 min) and acetone (15 s)
after 24 hours, washed in PBS, and incubated with the
anti-K18 antibody Ks 18.04 (Progen Biotechnik GmbH,
Heidelberg, Germany) [31]. After washing and exposure
to the secondary antibody, the glass slides were mounted
in ProLong® Gold antifade reagent with DAPI mounting
medium (Life Technologies Corporation, Eugene, OR,
USA). To quantify the percentage of disrupted cells, all
transfections were performed in triplicate and at least
100 cells were scored in each case. Cells were character-
ized as having normal-appearing or disrupted cytoskeletal
keratin network. Coomassie staining for total protein
lysates of transient transfected cells has shown equal
levels of proteins. Of note, the transfection efficiency was
similar in all subgroups and ranged between 50–70 %.
Results
To address the importance of K8/K18 variants in DILI,
800 well characterized DILI subjects were analyzed. Of
the examined subjects, 72 % were Caucasians, while
Hispanics and African-Americans each constituted 11 %
of the study cohort (Table 1). In 63 % of patients, DILI
was deemed to be very likely or definite, while <5 %
were scored as unlikely. Nearly 55 % of subjects hadTable 3 Distribution of selected keratin variants in the DILI and pop
Subgroup (#) K8 G62C K8 I63V K8 A333A
# 11/800 9/800 15/800
% 1.4 1.1 1.9
DILI Caucasian (577) # 10b 8 0
% 1.7 1.4 0
African-American (87) # 0 0 13c
% 0 0 14.9
Hispanic (88) # 0 0 2
% 0 0 2.3
Asian (25) # 0 0 0
% 0 0 0
Control Caucasian # 59/4,2961 30/4,2962 8/4,2983
% 1.4 0.7 0.2
African-American # 7/2,2001 3/2,2012 274/2,2013,
% 0.3 0.1 12.4
Hispanic # - 1/121 1/1218
% - 0.8 0.8
Asian # - 0/286 0/2869
% - 0 0
Superscript numbers highlight comparisons between specific subgroups and the re
of the frequency of the K8 G62C variant in Caucasian versus African-American controls
8P <0.0001; 9P <0.0001; 10P <0.02; 11P <0.0001; 12P <0.0001; 13P <0.0001. aAmino a
(K8 G62C+R341H); cone patient carries two K8/K18 variants (K8 A333A+G434S). DIhepatocellular injury at presentation, while 25 % and
20 % displayed a cholestatic and mixed damage pattern,
respectively. Fatal DILI was recorded in 9 % of patients
and 55 % of participants required hospitalization due to
their liver injury (Table 1).
The analysis of K8/K18 mutational hotspots revealed
heterozygous exonic and intronic K8/K18 variants in
101 (12.6 %) and 15 (1.9 %) patients, respectively
(Table 2). Amino acid-altering variants were found in 86
subjects (10.8 %; Table 2). K8 R341H constituted the
most frequent amino acid-altering variant found in 40
subjects (5 %; Fig. 1) and was particularly common
among Hispanics (9/88, 10.2 %; Table 2). On the other
hand, K8 A333A (13/87, 14.9 %) and K8 G434S (10/87,
11.5 %) variants were the most frequent variants among
African-Americans and the latter greatly contributed to
the fact that this ethnicity displayed a high percentage
of amino acid-altering variants (15/87, 17.2 %). K8
IVS6+46A>T represented the most common intronic
variant that was seen in ten patients (1.3 %; Fig. 1).
We also detected eight novel and hitherto undescribed var-
iants including five amino acid-altering (K8 K393R, K8
A351V, K8 A358V, K8 I346V, K18 D89H; Fig. 1; Additional
file 1: Figure S1). Four patients harbored compound
heterozygous variants (K8 G62C+R341H, K8 R341H+K18-
11C>T, K8 A333A+G434S, K8 I346V+IVS6+46A>T;
Table 2).ulation control groups by subgroup
K8 R341H K8 V380I K8 G434S K8 V480I Totala
40/800 3/800 10/800 7/800 86/800
5.0 0.4 1.3 0.9 10.8
27b 3 0 3 54
4.7 0.5 0 0.5 9.4
1 0 10c 4 15
1.2 0 11.5 4.6 17.2
9 0 0 0 11
10.2 0 0 0 12.5
1 0 0 0 2
4.0 0 0 0 8.0
259/4,2984,10 7/4,2975 1/3,9536 6/3,9807 406/4,300
6.0 0.2 0.03 0.2 9.4
8,9 35/2,2034,11 0/2,2035 169/2,0756,12,13 56/2,0867 388/2,203
1.6 0 8.1 2.7 17.6
14/12110,11 - 0/12112 0/121 16/121
11.6 - 0 0 13.2
7/286 - 0/28613 0/286 7/286
2.4 - 0 0 2.4
spective P values for these comparisons. For example, 1indicates a comparison
. 1P <0.0001; 2P <0.002; 3P <0.0001; 4P <0.0001; 5P = 0.1; 6P <0.0001; 7P <0.0001;
cid-altering variants are summarized; bone patient carries two K8/K18 variants
LI, drug-induced liver injury
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overrepresented among DILI subjects, we compared
their frequencies in DILI patients with data from public
databases. All common variants, as well as the total
amino acid-altering K8/K18 variants, were found at
comparable frequencies in DILI subjects and ethnically
matched controls (Table 3); and similar results were
obtained when only patients with high causality scores
(of 1, 2, 3) were analyzed (not shown). As reported pre-
viously, several variants segregated with specific ethnicities.
In particular, K8 G62C, I63V, R341H and V380I were over-
represented in Caucasians as compared to African-
American controls; whereas K8 A333A, G434S and V480I
were more common in African-Americans (Table 3). Al-
though the data on Hispanic and Asian controls were
rather limited, they demonstrated that K8 R341H is par-
ticularly common among Hispanics (that is, significantly
more common than in both African-Americans andTable 4 Distribution of keratin variants among DILI patients stratifie
Variant Severity
Fatal (5) Severe
# (%) # (%)
71 (8.9) 144 (18
K8 Y54H 0 0
K8 G62C 0 3 (2.1)
K8 I63V 1 (1.4) 2 (1.4)
IVS1+30G>A 0 0
K8 A333A 2 (2.8) 4 (2.8)
K8 R341H 5 (7.0) 5 (3.5)
K8 I346V 0 1 (0.7)a
K8 A351V 0 0
K8 A358V 0 1 (0.7)
K8 V380I 0 1 (0.7)
K8 K393R 1 (1.4) 0
IVS6+46A>T 0 3 (2.1)a
K8 G434S 1 (1.4) 4 (2.8)
K8 V461V 0 0
K8 V480I 1 (1.4) 3 (2.1)
IVS8+8C>T 0 1 (0.7)
IVS8+38G>A 0 0
IVS8+27del9nt 0 0
K18-11C>T 0 0
K18 Δ65-72 0 0
K18 D89H 1 (1.4) 0
# (%) patients with amino acid-altering variants 10 (14.1) 20 (13.
# (%) patients with intronic variants 0 4 (2.8)
aOne patient carries two K8/K18 variants (K8 I346V+IVS6+46A>T); bone patient carri
variants (K8 A333A+G434S); done patient carries two K8/K18 variants (K8 G62C+R34
moderate hospitalizedCaucasians), while African-American-enriched variants
(K8 A333A and G434S) are rare in this group (Table 3).
The most frequently implicated agents in our co-
hort included amoxicillin-clavulanate, isoniazid and
nitrofurantoin-induced DILI, and all these subgroups
displayed similar distribution of K8/K18 variants (see
Additional file 2: Table S1). Further analysis revealed
that K8/K18 variants are distributed similarly among
patients with different DILI causality or severity scores as
well as injury patterns (Tables 4, 5 and 6). However, there
is a trend of amino acid-altering keratin variants to asso-
ciate with fatal/severe DILI (14 %) as compared with
moderate/mild DILI (9.7 %; P = 0.09; Table 4) and this
trend became more obvious when only patients with high
causality scores were analyzed (14.3 % versus 8.7 %;
P = 0.05).
To better understand the biological significance of
these newly identified K8/K18 variants, we studied theird by severity
(4) Mod hosp (3) Mod (2) Mild (1) Total
# (%) # (%) # (%) # (%)
.0) 221 (27.6) 176 (22.0) 188 (23.5) 800 (100)
0 0 1 (0.5) 1 (0.1)
2 (0.9) 3 (1.7) 3 (1.6)d 11 (1.4)
2 (0.9) 1 (0.6) 3 (1.6) 9 (1.1)
1 (0.5) 0 0 1 (0.1)
5 (2.3) 1 (0.6)c 3 (1.6) 15 (1.9)
13 (5.9)b 7 (4.0) 10 (5.3)d 40 (5.0)
0 0 0 1 (0.1)
0 0 1 (0.5) 1 (0.1)
0 0 0 1 (0.1)
0 1 (0.6) 1 (0.5) 3 (0.4)
0 0 0 1 (0.1)
4 (1.8) 1 (0.6) 2 (1.1) 10 (1.3)
2 (0.9) 2 (1.1)c 1 (0.5) 10 (1.3)
0 1 (0.6) 0 1 (0.1)
2 (0.9) 1 (0.6) 0 7 (0.9)
0 0 0 1 (0.1)
1 (0.5) 0 0 1 (0.1)
1 (0.5) 0 0 1 (0.1)
1 (0.5)b 0 0 1 (0.1)
0 0 1 (0.5) 1 (0.1)
0 0 0 1 (0.1)
9) 21 (9.5) 15 (8.5) 20 (10.6) 86 (10.8)
8 (3.6) 1 (0.6) 2 (1.1) 15 (1.9)
es two K8/K18 variants (K8 R341H+K18-11C>T); cone patient carries two K8/K18
1H); DILI, drug-induced liver injury; Mod, moderate non-hospitalized; Mod hosp,
Table 5 Distribution of keratin variants among DILI patients stratified by causality scores
Variant Causalitye
Definitive Very likely Probable Possible Unlikely Total
# (%) # (%) # (%) # (%) # (%) # (%)
190 (23.8) 312 (39.0) 148 (18.5) 110 (13.8) 39 (4.8) 800 (100)
K8 Y54H 0 0 0 1 (0.9) 0 1 (0.1)
K8 G62C 3 (1.6) 5 (1.6)b 2 (1.4) 1 (0.9) 0 11 (1.4)
K8 I63V 2 (1.1) 3 (1.0) 2 (1.4) 0 2 (5.1) 9 (1.1)
IVS1+30G>A 0 0 1 (0.7) 0 0 1 (0.1)
K8 A333A 3 (1.6) 2 (0.6) 3 (2.3) 4 (3.6)d 3 (7.7) 15 (1.9)
K8 R341H 8 (4.2)a 14 (4.5)b 8 (5.4) 9 (8.2) 1 (2.6) 40 (5.0)
K8 I346V 0 1 (0.3)c 0 0 0 1 (0.1)
K8 A351V 1 (0.5) 0 0 0 0 1 (0.1)
K8 A358V 1 (0.5) 0 0 0 0 1 (0.1)
K8 V380I 1 (0.5) 0 0 1 (0.9) 1 (2.6) 3 (0.4)
K8 K393R 0 0 1 (0.7) 0 0 1 (0.1)
IVS6+46A>T 2 (1.1) 3 (1.0)c 4 (2.7) 1 (0.9) 0 10 (1.3)
K8 G434S 2 (1.1) 2 (0.6) 2 (1.4) 4 (3.6)d 0 10 (1.3)
K8 V461V 0 0 0 0 1 (2.6) 1 (0.1)
K8 V480I 0 5 (1.6) 2 (1.4) 0 0 7 (0.9)
IVS8+8C>T 1 (0.5) 0 0 0 0 1 (0.1)
IVS8+38G>A 0 0 0 1 (0.9) 0 1 (0.1)
IVS8+27del9nt 0 0 0 1 (0.9) 0 1 (0.1)
K18 -11C>T 1 (0.5)a 0 0 0 0 1 (0.1)
K18 Δ65-72 0 1 (0.3) 0 0 0 1 (0.1)
K18 D89H 0 1 (0.3) 0 0 0 1 (0.1)
# (%) patients with amino acid-altering variants 18 (9.5) 31 (9.9) 17 (11.5) 16 (14.6) 4 (10.3) 86 (10.8)
# (%) patients with intronic variants 4 (2.1) 3 (1.0) 5 (3.4) 3 (2.7) 0 15 (1.9)
aOne patient carries two K8/K18 variants (K8 R341H+K18-11C>T); bone patient carries two K8/K18 variants (K8 G62C+R341H); cone patient carries two K8/K18
variants (K8 I346V+IVS6+46A>T); done patient carries two K8/K18 variants (K8 A333A+G434S); ethe causality score was not known in one patient. DILI,
drug-induced liver injury
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K393R and K18 D89H variants were conserved both
among species and type I and II keratins, respectively,
which meshes well with the fact that they are located in
the particularly conserved amino-terminal (K18 D89H,
in an Asian patient with isoniazid-induced DILI) or
carboxy-terminal regions (K8 K393R, in a Caucasian pa-
tient with ezetimibe and simvastatin-induced DILI) of the
rod domain (Fig. 2) [2, 8]. Consistent with their biologically
predicted importance due to amino acid conservation, both
variants were found in patients with fatal DILI that other-
wise constitutes <10 % of our cohort (Table 4). Both vari-
ants were observed in cholestatic DILI and were not
detected among >300 Asian and >5,000 Caucasian controls
analyzed so far, or available in the above described public
databases (not shown). The K8 A358V variant was con-
served among K8 from different species but not among
other type II keratins and was detected in one subject withsevere DILI (Table 4; Additional file 3: Figure S2). On the
other hand, the non-conserved K8 A351V variant was ob-
served in a participant with mild DILI.
In vitro transfection experiments
To address the impact of the novel K8/K18 variants on
keratin filament network architecture, we performed
transient transfections in NIH 3T3 cells (Fig. 3). Import-
antly, both K8 K393R and K18 D89H, but not the other
K8/K18 variants, resulted in significantly more frequent
disruption of the keratin filament network (Fig. 3). Col-
lectively, these data suggest that rare K8/K18 variants
which result in disruption of the keratin cytoskeleton are
likely to predispose to severe DILI.
Discussion
Our results demonstrate that keratin variants are not
overrepresented in DILI patients, which contrasts with
Table 6 Distribution of keratin variants among DILI patients
stratified by laboratory injury profile
Variant Injury type
Hepatocellular Cholestatic Mixed Total
# (%) # (%) # (%) # (%)
438 (54.8) 198 (24.7) 164 (20.5) 800 (100)
K8 Y54H 0 1 (0.5) 0 1 (0.1)
K8 G62C 5 (1.1) 4 (2.0)c 2 (1.2) 11 (1.4)
K8 I63V 8 (1.8) 1 (0.5) 0 9 (1.1)
IVS1+30G>A 0 0 1 (0.6) 1 (0.1)
K8 A333A 4 (0.9) 7 (3.5)d 4 (2.4) 15 (1.9)
K8 R341H 21 (4.8)a 10 (5.0)c 9 (5.5) 40 (5.0)
K8 I346V 1 (0.2)b 0 0 1 (0.1)
K8 A351V 1 (0.2) 0 0 1 (0.1)
K8 A358V 0 1 (0.5) 0 1 (0.1)
K8 V380I 0 1 (0.5) 2 (1.2) 3 (0.4)
K8 K393R 0 1 (0.5) 0 1 (0.1)
IVS6+46A>T 7 (1.6)b 1 (0.5) 2 (1.2) 10 (1.3)
K8 G434S 5 (1.1) 5 (2.5)d 0 10 (1.3)
K8 V461V 1 (0.2) 0 0 1 (0.1)
K8 V480I 5 (1.1) 2 (1.0) 0 7 (0.9)
IVS8+8C>T 1 (0.2) 0 0 1 (0.1)
IVS8+38G>A 0 0 1 (0.6) 1 (0.1)
IVS8+27del9nt 1 (0.2) 0 0 1 (0.1)
K18 -11C>T 1 (0.2)a 0 0 1 (0.1)
K18 Δ65-72 1 (0.2) 0 0 1 (0.1)
K18 D89H 0 1 (0.5) 0 1 (0.1)
# (%) patients with
amino acid-altering
variants
46 (10.5) 27 (13.6) 13 (7.9) 86 (10.8)
# (%) patients with
intronic variants
10 (2.3) 1 (0.5) 4 (2.4) 15 (1.9)
aOne patient carries two K8/K18 variants (K8 R341H+K18-11C>T); bone patient
carries two K8/K18 variants (K8 I346V+IVS6+46A>T); cone patient carries two
K8/K18 variants (K8 G62C+R341H); done patient carries two K8/K18 variants
(K8 A333A+G434S); DILI, drug-induced liver injury
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biliary cirrhosis and ALF [8, 19]. This lack of overall associ-
ation of K8/K18 variants with DILI may, in part, be due to
the limited number of cases attributed to an individual
agent, since this cohort of 800 cases included over 250 in-
dividual drugs and herbal and dietary supplements. Along
these lines, previous reports suggested that K8/K18 vari-
ants predispose only to specific forms of liver injury. For
example, exonic variants were not found to predispose to
disease development in patients with hemochromatosis
[17], and transgenic animals carrying the K18 R90C variant
were markedly susceptible to Fas- but not TNFα-induced
apoptosis as well as to thioacetamide- but not carbon
tetrachloride-induced liver fibrosis [32].To evaluate the importance of K8/K18 variants in
DILI, we took advantage of large, publicly available data-
bases that allowed us to compare our results with a lar-
ger control population than the previous studies [8, 19].
Multiple K8/K18 variants were confirmed and shown to
associate with specific ethnic backgrounds [19, 30] and
R341H has been demonstrated to constitute the most
common amino acid-altering K8/K18 variant in Asians
(Table 3). In addition, K8 A333A, G434S and V480I
were largely restricted to African-Americans as com-
pared to both Asians and Hispanics. While the exact
reason for the enrichment of certain K8/K18 variants in
specific ethnic backgrounds remains unknown, unequal
ethnic distribution of human variants is relatively com-
mon and is caused by adaption to local factors [33, 34].
The data from publicly available databases indicate
that the frequency of several common variants is higher
than previous estimations. In particular, K8 G62C and
R341H variants were detected in 1.4 % and 6 % of US
Caucasian controls, respectively (versus 0.9 % and 3.2 %
as reported previously [19, 35]). These data should
therefore inform future studies that examine K8/K18
variants in different disease contexts.
While we found no overrepresentation of common
K8/K18 variants in DILI subjects, we observed a clear
trend towards clustering of these variants in the more
severe cases. However, due to the relatively low num-
bers, further studies are needed to confirm this observa-
tion that is reminiscent of the situation with ALF, where
the presence of K8/K18 variants was associated with
adverse outcomes [19]. Moreover, we detected several
previously unknown variants that are likely to have bio-
logical importance. As such, K8 K393R and K18 D89H
are the first described simple epithelial keratin variants
located in the most conserved helix initiation/termination
motifs (HIM/HTM) of the rod domain (Fig. 2e). Of note,
mutations in these domains have been presumed to be
embryolethal in humans [19, 35, 36] and represent the
most important and abundant disease-causing mutational
hotspots in epidermal keratins and other IFs (Fig. 2e)
[2, 8, 13, 37]. The observed keratin network disruption in
cells transfected with K8 K393R or K18 D89H further
strengthens their biological significance. Although the per-
formed transfection experiments cannot fully evaluate the
importance of both variants in vivo, the conserved K18
D89H represents a non-conservative substitution since it
alters protein charge. Moreover, it is only one residue away
from K18 R90C (Fig. 2) whose overexpression in trans-
genic mice causes a marked susceptibility to a variety of
drug-induced liver injuries [8, 35]. While K8 K393R might
be considered a conservative substitution, the same muta-
tion in a less conserved region of K5 (that is, K5 K199R)
was sufficient to cause EBS [38]. Hence, structural consid-
erations, cell culture experiments, transgenic mouse data
A B
C D
E
Fig. 2 K8 K393R and K18 D89H are the first identified simple epithelial keratin variants located in the most conserved regions of the rod domain.
Conservation of the novel K8 K393R/K18 D89H variants among (a,c) species and b type II or d type I keratins (standard single-letter amino acid
abbreviations are used). Sequences surrounding the novel K8/K18 variants are depicted. Dots highlight conserved amino acids. e Distribution of
simple epithelial and epidermal keratin variants within the keratin backbone. The schematic shows the characteristic tripartite structure (N-terminal
‘head’, central ‘rod’ and C-terminal ‘tail’ domains) of all IFs including keratins. The rod domain is subdivided into IA, IB, IIA, and IIB subdomains that
in turn are separated through linker (L1, L1-2, L2) sequences. The shaded regions are the most conserved segments of the rod domain (termed
helix initiation motif ‘HIM’ and helix termination motif ‘HTM’) and constitute mutation ‘hot spots’ in severe epidermal keratins and other IF mutations.
Note that unlike epidermal keratins, the frequent human K8/K18 variants are located outside HIM/HTM. IF, intermediate filament
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variants suffered fatal DILI collectively make a strong
case for the importance of these substitutions in
DILI outcomes.
Although the exact pathogenesis of DILI remains to be
clearly defined [22], K8/K18 deficiency results in
multiple cellular dysfunctions that likely contribute
to development/progression of this type of liver injury. For
example, keratins constitute important mechanoprotectiveproteins and K18 R90C mutation results in hepatocyte fra-
gility, while other tested keratin mutations that are not in
the HIM/HTM do not [35]. Furthermore, K8/K18 are
established anti-apoptotic genes [8] and may also protect
from hepatocyte necrosis as demonstrated in transgenic
mice that express K18 D238E/D397E which cannot be
cleaved by caspases during apoptosis [39]. Keratins are also
known to modulate organelle positioning, and impairment
in K8/K18 result in mitochondrial dysfunction and
Fig. 3 K8 K393R and K18 D89H variants result in keratin network disruption. a NIH 3T3 cells were transiently transfected with wild-type K8/K18 (WT) or
a combination of K8/K18 variants and a WT partner keratin and stained with an anti-K18 antibody. Transfections were performed in triplicate. b The
percentage of cells with disrupted keratin filaments was quantified. At least 100 cells were counted in each experiment
Usachov et al. BMC Medicine  (2015) 13:196 Page 10 of 12susceptibility to oxidative stress [40, 41]. Furthermore,
keratins act as signalling platforms and are important for
protein localization/targeting, modulation of protein syn-
thesis, cell growth or proliferation [3, 8, 42–44]. Al-
though the commonly found K8 variants do not result in
obvious keratin network redistribution under basal con-
dition, they do so under various stress situations such as
oxidative stress or upon hyperphosphorylation conditions
[45]. In that respect, K8 G62C/R341H/R341C variantspredisposed transgenic mice to acetaminophen-induced
liver injury and this predisposition was associated with a
more prominent keratin network disruption after the ex-
posure to the drug [46].
Fortunately severe clinical outcomes with DILI are un-
common, with less than 10 % of patients requiring a
liver transplant or dying within 6 months of DILI onset
[47]. However, additional genetic studies that focus on
the HIM/HTM domains of simple epithelial keratins are
Usachov et al. BMC Medicine  (2015) 13:196 Page 11 of 12likely to provide important information regarding the
prevalence of fatal DILI in individuals with HIM/HTM
keratin variants. We also anticipate that specific drugs,
and potentially specific race and ethnic background vari-
ants, are likely to play important roles in this process.
Conclusions
Our study has uncovered variants in highly conserved resi-
dues of K8 Lys393Arg and K18 Asp89His in patients with
fatal DILI. These first to be described novel variants repre-
sent for the first time described ‘epidermal-like’ K8/K18
variants which lead to keratin network disruption in
untreated cells. Common K8/K18 variants were found at
similar frequencies in DILI subjects and ethnically matched
population controls. Thus, rare K8/K18 variants may
predispose to DILI development in a subset of patients.
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